Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

David Blech, Jewish ‘King of Biotech’ Stocks, Fails To Get Sentence Tossed

David Blech, once dubbed the “King of Biotech”, failed to persuade a U.S. appeals court to throw out his four-year prison term for securities fraud on the ground that his sentencing judge was biased.

Blech, 58, had argued in court papers that U.S. District Judge Colleen McMahon improperly considered his race and social status in imposing the sentence.

The defendant, who is white, Jewish and was once among the wealthiest Americans, said McMahon wanted to counter a view that “we let people like you get away with things that we don’t let poor black drug addicts” get away with.

In an order on Tuesday, the 2nd U.S. Circuit Court of Appeals said McMahon “made a number of illconceived remarks that bordered on the inappropriate,” but that it was not persuaded that she sentenced Blech “based on unconstitutional factors such as race”.

It said McMahon sentenced Blech based on factors including “the need for specific deterrence for a recidivist, and the need for general deterrence for those who might otherwise feel that some whitecollar crimes are ‘games worth playing.’”

The court also upheld McMahon’s $1.34 million forfeiture order, saying Blech waited too long to object.

Richard Levitt, a lawyer for Blech, declined to comment. The defendant had sought to be resentenced by a different judge.

Blech, who has said he has bipolar disorder, had pleaded guilty in May 2012 to manipulating shares of biopharmaceutical companies Pluristem Therapeutics Inc and Intellect Neurosciences Inc in 2007 and 2008.

He reached a $1.03 million civil settlement last August with the U.S. Securities and Exchange Commission.

Blech had also pleaded guilty in 1998 to an unrelated fraud, but was sentenced to probation.

Earlier in his career, Blech helped found Celgene Corp , whose products include the blood cancer drug Revlimid, and whose market value on Friday topped $68 billion.

He also helped found Icos Corp, now part of Eli Lilly & Co , which developed Cialis to treat erectile dysfunction.

Forbes magazine said Blech was worth $295 million in 1992, making him among the 400 richest Americans.

Blech is housed at a low-security prison in Fort Dix, New Jersey. He is not eligible for release until March 12, 2017.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you move on, I wanted to ask you to support the Forward’s award-winning journalism during our High Holiday Monthly Donor Drive.

If you’ve turned to the Forward in the past 12 months to better understand the world around you, we hope you will support us with a gift now. Your support has a direct impact, giving us the resources we need to report from Israel and around the U.S., across college campuses, and wherever there is news of importance to American Jews.

Make a monthly or one-time gift and support Jewish journalism throughout 5785. The first six months of your monthly gift will be matched for twice the investment in independent Jewish journalism. 

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version